'Results from MGC Pharma's double-blind Phase II trial on COVID-19 patients in Israel are due in early August, so they could come any day now. When the results arrive, investors should be keeping a keen eye on whether ArtemiC can successfully minimize the body's immunological response to COVID-19, and to what extent'.
MXC Price at posting:
2.2¢ Sentiment: Hold Disclosure: Held
